CD40L activation of human RPE cells
1 August 2018
| Graham Wallace
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is the leading cause of reduced visual acuity in the elderly worldwide. The risk factors involved in AMD include smoking and diet, while genetics have been shown to have a significant role. Recently a link between...
Diagnosis of ocular tuberculosis
1 August 2018
| Nikolaos D Georgakarakos
|
EYE - Vitreo-Retinal
This review article provides an update on the methods diagnosing ocular tuberculosis (TB), the difficulties in making the diagnosis and makes recommendations to a more accurate diagnosis by combining the available diagnostic tests. Today ocular TB remains a presumptive clinical...
Medical malpractice in uveitis: a review of clinical entities and outcomes
1 August 2018
| Nikolaos D Georgakarakos
|
EYE - Vitreo-Retinal
This paper presents a retrospective review of malpractice verdicts, rulings and settlements in the United States. Twenty-five cases of uveitis-related litigation spanning 1971-2014 were identified from the database representing 2.3% of all cases. Forty-eight percent of the cases were infectious....
ABCA1 mediates lipid efflux in the retina
1 June 2018
| Graham Wallace
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population. There are two forms of AMD, dry and wet, the latter so named because of the presence of choroidal neovascularisation. Both forms lead to retinal pigment...
ANGPTL-4 inhibition reduces inflammation in diabetic retinopathy
1 June 2018
| Graham Wallace
|
EYE - Vitreo-Retinal
Diabetic retinopathy (DR) is the most common cause of blindness in working-age humans, and numbers are rising due to increased cases of type 2 diabetes (T2D). T2D is associated with increased obesity and dyslipidaemia, which is a major risk factor...
OCTA use in CNV associated with CSR
1 June 2018
| Saruban Pasu
|
EYE - Vitreo-Retinal
The aim of this study was to assess the rate of choroidal neovascularisation (CNV) in chronic central serous chorioretinopathy (CSR) patients with flat irregular pigment epithelial detachments (PEDs) by optical coherence tomography angiography (OCTA). Data of all consecutive patients with...
Safety and outcome of microincision vitreous surgery in uveitis
1 June 2018
| Nikolaos D Georgakarakos
|
EYE - Vitreo-Retinal
This paper reports the outcomes of microincision vitreous surgery (MIVS) 23G/25G in uveitis of 103 patients (106 eyes) who underwent diagnostic MIVS over a period of four years at the Advanced Eye centre in Chandigarth India. The postoperative evaluation included...
Effectiveness and Safety of Dexamethasone implants for post surgical macular oedema including Irvine-gass syndrome
1 April 2018
| Jonathan Chan
|
EYE - Vitreo-Retinal
This is a retrospective, multicentre, uncontrolled, consecutive case series from Lyon, France between April 20111 to June 2014, with minimum of one year follow-up. The clinical features including the best corrected acuity (BCVA), central subfield macular thickness (CSMT) and intraocular...
Management of giant retinal tears with vitrectomy and perfluorocarbon liquid postoperatively as a short-term tamponade
1 April 2018
| Saruban Pasu
|
EYE - Vitreo-Retinal
The authors report an eight year retrospective case series study of 30 eyes of 29 patients with who underwent a giant retinal tear-related retinal detachment repair. M: F ratio was 23:6. Right to left eye ratio was 16:14. The mean...
Somatostatin protects retinal pericytes
1 April 2018
| Graham Wallace
|
EYE - Vitreo-Retinal
Diabetic retinopathy (DR) is a complication of diabetes, caused by high blood sugar levels damaging the retinal microvasculature. Mechanisms, such as oxidative stress and deposition of advanced glycation end products, leads to glial cell activation and neuronal apoptosis. Pericytes, contractile...
Subfoveal choroidal thickness and PCV
1 April 2018
| Saruban Pasu
|
EYE - Vitreo-Retinal
This report studies the prognostic factors for visual improvement and the need for additional treatments at one year after the initial combination therapy of intravitreal ranibizumab injection or intravitreal aflibercept injection followed by PDT in eyes with PCV. Fifty-six eyes...
Systemic pharmacology of intravitreal anti-VEGF
1 April 2018
| Saruban Pasu
|
EYE - Vitreo-Retinal
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
